

Reference number(s)
1815-A

SPECIALTY GUIDELINE MANAGEMENT

ALUNBRIG (brigatinib)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indication

Alunbrig is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

B. Compendial Uses

1. Recurrent, advanced or metastatic ALK rearrangement-positive NSCLC as a single agent
2. Brain metastases from ALK rearrangement-positive NSCLC as a single agent
3. Inflammatory myofibroblastic tumor (IMT) with ALK translocation as a single agent

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review: ALK mutation status

III. CRITERIA FOR INITIAL APPROVAL

A. **Non-Small Cell Lung Cancer (NSCLC)**

Authorization of 12 months may be granted for treatment of recurrent, advanced, or metastatic ALK-positive NSCLC (including brain metastases from NSCLC) as a single agent.

B. **Inflammatory Myofibroblastic Tumor (IMT)**

Authorization of 12 months may be granted for treatment of ALK-positive IMT as a single agent.

IV. CONTINUATION OF THERAPY

A. **Non-Small Cell Lung Cancer (NSCLC)**

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when there is no evidence of unacceptable toxicity while on the current regimen.

B. **Inflammatory Myofibroblastic Tumor (IMT)**

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

Reference number(s)
1815-A

V. REFERENCES

1. Alunbrig [package insert]. Cambridge, MA: ARIAD Pharmaceuticals, Inc.; May 2020.
2. The NCCN Drugs & Biologics Compendium® © 2021 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed February 22, 2021.